MODIFIED OLIGOPEPTIDES FOR TREATING PANCREATITIS, GASTRIC ULCERS AND OTHER HYPERENZYMEMIAS BASED ON A PEPTIDIC ENZYME INHIBITOR AND METHOD FOR PRODUCING SAID MODIFIED OLIGOPEPTIDES

摘要

The invention can be used to create oral and parenteral drugs in pharmaceutics and medicine for the treatment of pancreatitis, gastric ulcers and other hyperenzymemias. The modified oligopeptides for treating pancreatitis, gastric ulcers and other hyperenzymemias based on peptidic enzyme inhibitors are characterized in that a mixture (ensemble) of chemically modified oligopeptides is used as the main active agent, said oligopeptides being the product of the autologous hydrolysis of the proteolytic enzymes trypsin, chymotrypsin and papain, and the charges of the oligopeptide molecules being changed to opposite charges by acylation with succinic anhydride and alkylation with monochloroacetic acid. The resultant mixture (ensemble) of modified oligopeptides rapidly stops the inflammatory process caused by the excessive secretion of proteolytic enzymes. The process of manufacturing the proposed drug is simple, economically viable, environmentally benign, produces zero waste and comprises three stages. As a result of the effect of selective complementary hybridization, the peptides produced interact only with their precursor enzymes, thus inhibiting the function thereof. The low molecular weight of the peptides produced and their resistance to hydrolytic enzymes enables them to easily cross biological membranes, be absorbed from the intestines, and build up in the nidus with a high concentration of target enzymes. These properties make it possible for the proposed peptides to be used to produce, inter alia, oral drug forms for the treatment of chronic pancreatitis and gastric ulcers.